- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04941183
Phase 1 Study to Assess Safety, Tolerability, PD, PK, Immunogenicity of IV NTR-441 Solution in Healthy Volunteers and COVID-19 Patients
January 18, 2024 updated by: Neutrolis
A Randomized, Placebo-controlled, Double-blind, Single-ascending-dose and Multiple-ascending-dose, Phase 1 Study to Assess the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of IV NTR-441 Solution in HV Adults and COVID-19 Patients
This first-in-human clinical study is a Phase 1a/ 1b, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and PK/PD of NTR-441 in healthy subjects and patients with COVID-19 after single ascending IV infusion doses and multiple ascending IV infusion doses.
Study Overview
Study Type
Interventional
Enrollment (Actual)
52
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 97 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Healthy volunteers:
Inclusion Criteria:
- Male or female, non-smoker, ≥18 and ≤55 years of age, with Body Mass Index (BMI) > 18.5 and < 32.0 kg/m2
- Healthy with no clinically significant findings, determined by medical evaluation (medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory evaluations) at Screening
- Subject is able to understand and is willing to comply with all study requirements, and willing to follow the instructions of the study staff.
- Subject voluntarily agrees to participate in this study.
Exclusion Criteria:
- Pregnancy, nursing, and/or breastfeeding.
- Study participant has a history of an anaphylactic reaction.
- Subject has used an investigational drug within 30 days (or 5 half-lives whichever is longer) prior to the first dose of study drug.
- Has received any prescription or nonprescription over-the-counter (except occasional use of acetaminophen, paracetamol or ibuprofen) medication, topical medications, vitamins, dietary or herbal during the last 14 days or 5 half-lives, whichever is longer.
- Subject has a positive urine test for drugs of abuse at the screening visit or admission.
- Regular consumption of alcohol within 6 months prior to Screening or use of illicit substances within 3 months prior to screening.
- Subject has positive test for SARS-CoV-2 infection, human immunodeficiency virus (HIV), chronic or active hepatitis B, or active hepatitis C.
- Donation or loss of blood or plasma within 4 weeks prior to initial dosing.
- Subject has a history or current evidence of a serious and/or unstable cardiovascular, respiratory, gastrointestinal, hematologic, autoimmune, mental or other medical disorder, including cirrhosis or malignancy; a history of a psychiatric disorder that will affect the subject's ability to participate in the study.
- Subject has a clinically relevant abnormal ECG; abnormal laboratory values.
- Subject has hypertension.
COVID-19 patients:
Inclusion Criteria:
- Male or female, non-smoker, ≥18 years of age.
- Participant has active laboratory-confirmed SARS-CoV-2 infection.
- Participant must be hospitalized for COVID-19 pneumonia.
- Ability to provide informed consent personally, or by a legally acceptable representative if the participant is unable to do so.
Exclusion Criteria:
- Pregnancy, nursing, and/or breastfeeding.
- History of an anaphylactic reaction.
- In the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments.
- Severely immune-compromised participants.
- Participant known to test positive for human immunodeficiency virus (HIV), chronic or active hepatitis B, or active hepatitis C.
- Any other clinical conditions that in the opinion of the Investigator would make the participants unsuitable for the study.
- Prior treatment with any investigational drug therapy against coronavirus infection within 5 half-lives, prior to enrollment
- Participants who have received an experimental (or, in future, potentially a licensed) immunization or remdesivir against coronavirus remain eligible.
- Participation in another clinical study with the study intervention administered from 30 days or 5 half-lives whichever is longer.
- Anticipated transfer to another hospital which is not a study site during the intervention period.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NTR-441
Single Ascending Dose; Multiple Ascending Dose.
|
NTR-441
|
Placebo Comparator: Placebo
Single Ascending Dose; Multiple Ascending Dose.
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate safety and tolerability of single and multiple ascending doses of NTR-441 solution administered intravenously (IV) to adults
Time Frame: 60 days
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 following a single or multiple IV of NTR-441.
|
60 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of maximum plasma concentration (Cmax)
Time Frame: 15 days
|
Maximum plasma concentration
|
15 days
|
Measurement of time of maximum plasma concentration (Tmax)
Time Frame: 14 days
|
Time of maximum plasma concentration
|
14 days
|
Measurement of area under the concentration-time curve
Time Frame: 15 days
|
Area under the concentration-time curve from predose to the time of the last quantifiable concentration
|
15 days
|
Measurement of the terminal elimination rate (λz)
Time Frame: 15 days
|
Terminal elimination rate
|
15 days
|
Measurement of terminal elimination half-life (t½)
Time Frame: 15 days
|
Terminal elimination half-life
|
15 days
|
Measurement of total body clearance (CL/F)
Time Frame: 15 days
|
Total body clearance
|
15 days
|
Measurement of apparent volume of distribution
Time Frame: 15 days
|
Apparent volume of distribution
|
15 days
|
To assess for immunogenicity of NTR-441 following single ascending and multiples ascending doses of NTR-441 solution administered IV to adults
Time Frame: 30 days
|
Concentration of anti-drug antibodies of NTR-441 following single and multiples doses of NTR-441 solution administered IV
|
30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 14, 2021
Primary Completion (Actual)
December 12, 2022
Study Completion (Actual)
June 6, 2023
Study Registration Dates
First Submitted
May 4, 2021
First Submitted That Met QC Criteria
June 24, 2021
First Posted (Actual)
June 28, 2021
Study Record Updates
Last Update Posted (Estimated)
January 19, 2024
Last Update Submitted That Met QC Criteria
January 18, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NTR441-1001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States